Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

Item

http://www.wikidata.org/entity/Q36333136

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

@ast

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

@en

type

Item

label

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

@ast

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

@en

prefLabel

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

@ast

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

@en

P1476

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.

@en

P2093

Daniel R Jacobson

http://www.w3.org/2001/XMLSchema#string

Robert J Cersosimo

http://www.w3.org/2001/XMLSchema#string

P2860

Development and characterization of novel erythropoiesis stimulating protein (NESP)

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

Clinical and economic comparison of epoetin alfa and darbepoetin alfa.

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.

P304

58-65; quiz 169-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G042

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16332942

http://www.w3.org/2001/XMLSchema#string

P921

Darbepoetin alfa

chemotherapy